Author： Brache V Faundes A Alvarez F
Publisher： Informa Healthcare
ISSN： 1474-0338
Source： Expert Opinion on Drug Safety, Vol.2, Iss.3, 2003-05, pp. : 321-332
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Risk–benefit effects of tocolytic therapy
By Pryde Peter G Janeczek Susan Mittendorf Robert
Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. :
Access to resources
Recommend
Cardiovascular Risk-Benefit Profile of Sibutramine
By Scheen A.J.
American Journal of Cardiovascular Drugs, Vol. 10, Iss. 5, 2010-10 ,pp. :
A Risk-Benefit Assessment of Abciximab in Angioplasty
By Kleiman N.S.
Drug Safety, Vol. 20, Iss. 1, 1999-01 ,pp. :